Hematopoietic Cell and Renal Transplantation in Plasma Cell Dyscrasia Patients
Overview
General Surgery
Authors
Affiliations
Gammopathies, multiple myeloma, and amyloidosis are plasma dyscrasias characterized by clonal proliferation and immunoglobulin overproduction. Renal impairment is the most common and serious complication with an incidence of 20-30% patients at the diagnosis. Kidney transplant has not been considered feasible in the presence of plasma dyscrasias because the immunosuppressive therapy may increase the risk of neoplasia progression, and paraproteins may affect the graft. However, recent advances in clinical management of multiple myeloma and other gammopathies allow considering kidney transplant as a possible alternative to dialysis. Numerous evidence indicates the direct relationship between hematological remission and renal function restoring. The combination of kidney and hematopoietic cell transplant has been reported as a promising approach to reestablish end-organ function and effectively treat the underlying disease. This review describes current protocols used to perform kidney transplantation in patients with plasma dyscrasias.
Risk of relapse of multiple myeloma following kidney transplantation.
Shah S, Ibrahim M, Delaney M, Schey S, Bygrave C, Streetly M Clin Kidney J. 2019; 12(2):216-223.
PMID: 30976399 PMC: 6452174. DOI: 10.1093/ckj/sfy137.
Multiple myeloma and kidney transplantation: the beginning of a new era.
Van den Bosch I, Sprangers B, Gertz M Clin Kidney J. 2019; 12(2):213-215.
PMID: 30976398 PMC: 6452187. DOI: 10.1093/ckj/sfz003.
Cerebral Small Vessel Disease.
Li Q, Yang Y, Reis C, Tao T, Li W, Li X Cell Transplant. 2018; 27(12):1711-1722.
PMID: 30251566 PMC: 6300773. DOI: 10.1177/0963689718795148.
Bhowmik D, Yadav S, Kumar L, Agarwal S, Agarwal S, Gupta S Indian J Nephrol. 2017; 27(4):324-326.
PMID: 28761239 PMC: 5514833. DOI: 10.4103/ijn.IJN_169_16.